ASTRAZENECA PHARMA INDIA LTD. - Launch Of Tremelimumab (Imjudo)

Download	< Back
20 Sep 2024
We refer to our earlier communication dated June 1, 2023, intimating the receipt of Import and Market permission in Form CT-20 from Drugs Controller General of India for Tremelimumab (Imjudo) concentration for solution for infusion 20 mg/ml (25 mg/ml and 300 mg/15 ml presentations in single dose vials) administered through intravenous route. With regard to the same, we wish to further update that the Company will launch Trmelimumab (Imjudo) in October 2024 in India.
View all announcements for ASTRAZENECA PHARMA INDIA LTD.	Source: BSE India

Stocks	Mutual Funds		Investment tracking
A-Z Gainers - Daily \| Weekly \| Monthly Losers - Daily \| Weekly \| Monthly Group-wise listing IPO \| Top IPOs Recent IPOs \| IPO News Similar Price band Most traded - By volumes Top 100 - By market capitalisation Latest Company Results Management Speaks Market News	Top 25 schemes High-risk, High-returns Medium-risk, Medium-returns Low-risk, Low-returns Gilt Funds Funds of Funds Special Funds Liquid Funds Dynamic Asset Allocation NFOs MF Selector	Equity - ELSS Equity - Index Funds Equity - Sector Funds Equity - Balance Fund Equity - Diversified Fund MF News Budget 2024	My Portfolio My Watch List If You Had Invested... Global Indicators Forex Converter Market Indices Sectoral Indices World Indices Market Astrology Advertise with us